XDNA Performance — Kelly CRISPR & Gene Editing Technology ETF
Data updated: 2024-11-13
XDNA returned −35.77% over one year to Nov 2023. Over one year the fund trailed its Technology Equity category average: $100 grew to $64, against $128 for the category. Volatility over the past 12 months was 37.91% a year. In the 12 months to Nov 2023 the fund took in a net $1.8M, and assets reached $2.59M.
XDNA Growth of $100
What $100 invested in Kelly CRISPR & Gene Editing Technology ETF grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Technology Equity category average over the same months.
| Period | XDNA | Category average |
|---|---|---|
| 1 year (Dec 2022 – Nov 2023) | $64 | $128 |
| Since data start (Jan 2022 – Nov 2023) | $50 | $89 |
XDNA Trailing Returns
Total returns to Nov 2023, from SEC N-PORT.
| Period | Total return |
|---|---|
| 1 year | −35.77% |
XDNA Annual Returns
Calendar-year total returns of Kelly CRISPR & Gene Editing Technology ETF, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2023 (Jan–Nov) | −25.63% |
| 2022 | −32.34% |
XDNA Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | +11.5% | −7.5% | −13.1% | +0.6% | +0.9% | −2.0% | +4.8% | −12.0% | −10.6% | −15.1% | +19.3% | — |
| 2022 | −7.6% | −1.6% | −7.0% | −20.0% | −2.1% | +4.3% | +21.5% | +0.9% | −6.0% | +1.1% | −2.6% | −13.6% |
XDNA Risk
Risk measures from monthly returns over Dec 2022 – Nov 2023.
- 1-year volatility (annualised): 37.91%
- Best month: +19.32% (Nov 2023)
- Worst month: −15.07% (Oct 2023)
XDNA Fund Flows
Monthly money in and out of Kelly CRISPR & Gene Editing Technology ETF, from SEC Form N-PORT.
- 12-month net flow: $1.8M
- 12-month gross sales (incl. reinvestments): $783K
- Sales ÷ redemptions: -0.79×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Nov 2023 | $337K | $0 | $337K |
| Oct 2023 | $0 | $0 | $0 |
| Sep 2023 | $0 | $0 | $0 |
| Aug 2023 | $206K | $0 | $206K |
| Jul 2023 | $0 | $0 | $0 |
| Jun 2023 | $0 | $0 | $0 |
| May 2023 | $240K | $0 | $240K |
| Apr 2023 | $0 | $0 | $0 |
| Mar 2023 | $0 | $0 | $0 |
| Feb 2023 | $0 | $0 | $0 |
| Jan 2023 | $0 | $0 | $0 |
| Dec 2022 | $0 | −$987K | $987K |
XDNA Assets Under Management
Net assets of Kelly CRISPR & Gene Editing Technology ETF by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2023-11-30 | $2.59M |
| 2023-08-31 | $2.45M |
| 2023-05-31 | $2.48M |
| 2023-02-28 | $2.56M |
| 2022-11-30 | $4.03M |
| 2022-08-31 | $5.29M |
| 2022-05-31 | $973.12K |
| 2022-02-28 | $1.34M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.